BioSpace News Archive

Fortress Biotech, Inc. today announced that Lindsay A. Rosenwald, M.D., Chairman, President and Chief Executive Officer, will present a corporate overview at the BTIG Virtual Biotechnology Conference on Tuesday, August 8, 2023 at 12:00 PM ET.

North America’s largest pure-play distributor of scientific and controlled environment products, Thomas Scientific, has completed the acquisition of Massachusetts -based cleanroom, packaging, and industrial products provider Quintana Supply.

Signati™️ Medical, Inc. announced today that Dr. LeRoy Jones has been appointed to its Board of Directors.

Elevar Therapeutics, Inc. today announced it will host a virtual key opinion leader (KOL) event on August 10, 2023, at 10 a.m. ET to discuss the Phase 3 study of rivoceranib in combination with camrelizumab in unresectable hepatocellular carcinoma (uHCC).

BioSkryb Genomics, a pioneer in comprehensive single-cell multiomic research solutions, optimized a high-throughput workflow of BioSkryb’s ResolveDNA® Single-Cell Whole Genome Amplification technology on HP’s new D100 Single Cell Dispenser to deliver single-cell genomics at scale.

Results from XyloCor Therapeutics’ Phase 1 Portion of EXACT Trial of XC001 for Cardiovascular Disease Published in Circulation: Cardiovascular Interventions.

Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced financial results for the second quarter ended June 30, 2023.

Kindeva Drug Delivery (Kindeva), a premier global drug delivery device contract development and manufacturing organization (CDMO), announced that the company has received a grant from the U.K. Government’s Life Sciences Innovation Manufacturing Fund (LSIMF), unlocking a £33 million investment with Kindeva toward enhancing inhaler manufacturing and sustainability.

TrialAssure, a leading software-as-a-service (SaaS) provider advancing clinical trial disclosure, data sharing, and transparency, announced today that it is collaborating with MMS, a global clinical research organization, on a new artificial intelligence (AI) initiative aimed at developing generative text specifically for medical writing in the field of drug development.

Lexicon Pharmaceuticals, Inc., reported financial results for the three months ended June 30, 2023 and provided an update on key corporate milestones.